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The in vitro antiplasmodial activity of some 3-trifluoromethyl-2-
carbonylquinoxaline di-N-oxide derivatives is reported. The evaluation
was performed on cultures of FcB1 strain (chloroquine-resistant) of
P. falciparum and the most interesting compounds were then evaluated
on MCF7 tumor cells in order to evaluate an index of selectivity. The
7-methyl (2b, 4b, 5b, 6b) and nonsubstituted (3c, 4c, 5c) quinoxaline
1,4-dioxide derivatives presented the best level of activity.
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INTRODUCTION
Malaria remains one of the most widespread health
threats in the tropics with 300 to 500 million cases every
year and two million deaths (Greenwood et al., 2005). The
major concern in the treatment of this disease is the
possible growing resistance of Plasmodium falciparum to
the limited arsenal of antimalarial drugs. Chloroquine, a
traditional old antimalarial drug, is believed to exert its
activity by inhibiting hemozoin formation in the digestive
vacuole of the malaria parasite, but the mechanism of
Plasmodium falciparum resistant to chloroquine remains
unknown. Recently, some pyrrolo-quinoxaline derivatives
have shown antimalarial activity correlated with a high
inhibitory of ß-hematin formation (Guillon et al., 2004),
suggesting a bioisosteric relationship between the
quinoline and pyrrolo-quinoxaline rings.
Based on these statements and the urgent need to
develop new antimalarial drug candidates, we researched the
in vitro antimalarial activity of lead compounds in our library
containing the quinoxaline di-N-oxide subunit (Scheme 1),
which were previously shown to have good antituberculosis
activity (Zarranz et al., 2003; Jaso et al., 2003).
MATERIAL AND METHODS
Chemistry
Melting points were determined with a Mettler
FP82+FP80 apparatus (Greifense, Switzerland) and have not
been corrected. The 1H NMR spectra were recorded on a
Bruker AC-200E instrument (200 MHz) and Bruker 400
Ultrashield® (400 MHz), using TMS as the internal standard
and with DMSO-d6 and CDCl3 as the solvent; the chemical
shifts are reported in ppm (d) and coupling constant (J) values
are given in Hertz (Hz). Signal multiplicities are represented
by: s (singlet), d (doublet), t (triplet), q (quadruplet), dd
(double doublet) and m (multiplet). The IR spectra were
performed on a Perkin Elmer 1600 FTIR (Norwalk, CT,
USA) using KBr pellets; the frequencies are expressed in cm-1.
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Elemental microanalyses were obtained on an Elemental
Analyzer (Carlo Erba 1106, Milan, Italy) from vacuum-dried
samples. The analytical results for C, H, and N were within
± 0.4 of the theoretical values.
Alugram® SIL G/UV254 (Layer: 0.2 mm) (Macherey-
Nagel GmbH & Co. KG. Postfach 101352. D-52313 Düren,
Germany) was used for Thin Layer Chromatography and
Silica gel 60 (0.040-0.063 mm) for Column flash
Chromatography (Merck). HPLC conditions: Column Nova
Pack C18 60 A 4 mm (3.9×150 mm); mobile phase:
acetonitrile/water (60:40); flux: 1 mL/min.
Chemicals were purchased from E. Merck
(Darmstadt, Germany), Scharlau (F.E.R.O.S.A., Barce-
lona, Spain), Panreac Química S.A. (Montcada i Reixac,
Barcelona, Spain), Sigma-Aldrich Química, S.A.,
(Alcobendas, Madrid), Acros Organics (Janssen
Pharmaceutical 3a, 2440 Geel, België) and Lancaster
(Bischheim-Strasbourg, France).
Synthesis of 2-alkylcarbonyl and 2-benzoyl-3-trifluoro-
methyl-quinoxaline 1,4-di-N-oxide derivatives
The compounds under study were previously
synthesized and reported by our group (Zarranz et al.,
2004). Syntheses of the compounds were carried out by
the classical Beirut reaction (Scheme 1). The appropriate
benzofuroxane and the corresponding 1-(alkyl/phenyl)-
4,4,4-trifluoromethyl-β-diketone were dissolved in dry
chloroform in the presence of triethylamine, which acted
as the catalyst. When the reaction ended, the solvent was
evaporated to dryness, and a yellow crude solid or brown
oil was obtained. Each compound was purified by either
recrystallization or flash chromatography. The starting
compounds, 5-substituted or 5,6-disubstituted
benzofuroxanes, 1(a–g), were obtained by previously
described methods (Scheme 1) (Ortega et al., 2002).
Antiplasmodial Drug Assay
In vitro activity against P. falciparum (chloroquine-
resistant strain FcB1 was evaluated by a micromethod,
using the lactate dehydrogenase (LDH) enzyme of P.
falciparum (5).
Erythrocytes infected with P. falciparum, from
parasite cultures, were resuspended in the complete
culture medium at a haematocrit of 1.5% and distributed
into 96-well, microtitre plates (200 µL/well). For each
assay, the parasite culture was incubated with the drug for
48 h in 5% CO2, at 95% relative humidity, and then frozen
until the biochemical assay could be run.
SCHEME 1. aReagents: (i) 1,1,1-trifluoro-2,4-pentanedione, (ii) 1,1,1-trifluoro-2,4-hexanedione, (iii) 1,1,1-trifluoro-
5-methyl-2,4-hexanedione, (iv) 1,1,1-trifluoro-5,5-dimethyl-2,4-hexanedione and (v) 4,4,4-trifluoro-1-phenyl-1,3-
butanedione; in dry chloroform.
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A 20 µL subsample of the contents of each well was
mixed with 100 µL of a substrate solution containing 20 mg
sodium L-lactate (Sigma), 5.5 mg TRIS (Sigma) and 3.7 mg
3-acetyl pyridine adenine dinucleotide (APAD; Sigma)/mL.
After incubation for 30 min at 37 °C, 25 µL of a mixture of
NBT (1.6 mg/mL; Sigma) and PES (0,1 mg/mL, Sigma)
were added to each well. After another 35 min of
incubation, the formation of the reduced form of APAD was
measured at 650 nm, using a spectrophotometer (Polarstar
BMG). IC50 values were determined graphically in
concentration versus inhibition percent curves.
Cytotoxicity Tests
General Procedures. Human breast adenocarcinoma
(MCF-7) cells were cultured in DMEM culture medium
containing L-glutamine (2 mM) (Biowittaker), supplied with
5% of fetal calf serum (FCS) (Sigma), and incubated under
standard conditions (37 °C, 5% CO2). The cells were
trypsinized, resuspended in DMEM containing 5% FCS, and
seeded (20000 cells/well) in 96-well plates. Cell viability was
evaluated measuring the activity of the mitochondrial
enzyme succinate dehydrogenase. This test used sodium 3,3-
[1(1-phenyl amino carboxyl)-3-4-tetrazolium bis (4-
methoxy-6 nitro)] benzene sulfonic acid hydrate] (XTT)
(Sigma) as substrate, which was converted to a formazan
product, detected spectrophotometrically at 450 nm.
Screening Test. The cells were treated for 48 h with
drug concentrations ranging from 1 to 100 µg/mL. After
48 h of drug exposure, the medium was replaced by 50 µL
of a XTT solution (0.5 mg/mL), and the cells were
incubated for 180 min. The IC50 values were determined
graphically in concentration versus inhibition percent
curves (Tabbi et al., 2002).
RESULTS AND DISCUSSION
The 3-trifluoromethyl-2-carbonylquinoxaline di-N-
oxide derivatives were initially assayed in order to deter-
mine their ability to inhibit P. falciparum (chloroquine
resistant) (Delhaes et al., 1999; Tabbi et al., 2002) and the
results are shown in table 1. Interesting, compounds 3c,
4b, 4c, 5b, 5c and 6b demonstrated a satisfactory
inhibition with IC50 values of 2.4, 1.9, 2.0, 2.1, 1.2 and 1.7
µM, respectively. Contrary to the works of Guillon and co-
workers (Guillon et al., 2004), the antiplasmodial activity
of derivatives 3c, 4b, 4c, 5b, 5c and 6b does not appear to
interfere with β-hematin formation (data not shown).
In order to determine the potential cytotoxic profile
of quinoxaline di-N-oxide derivatives and establish the
selectivity index, compounds 3c, 4b, 4c, 5b, 5c and 6b
were evaluated on MCF7 tumor cells. The selectivity
index (SI) was defined as the ratio of the IC50 value for the
human cells (MCF7 cells) to the IC50 for the P. falciparum
strain under study. The IC50 values for the tumor cells are
as follows: 13.9 µM for 3c, 10.8 µM for 4b, 11.3 µM for
4c, and 18.9 µM for 5b, all of which have shown the best
TABLE I - In vitro sensitivity of chloroquine-resistant strain
(FcB1) of P. falciparum and in vitro cytotoxicity on MCF7
cells.
Compd. Ra Rb Rc IC50 (µM)
FcB1 MCF7
2a CH3 CH3 CH3 24 ND
2b CH3 H CH3 3.1 ND
2e Cl Cl CH3 >30 ND
2g F F CH3 23.7 ND
3a CH3 CH3 CH2CH3 16.5 ND
3b CH3 H CH2CH3 15.3 17.6
3c H H CH2CH3 2.4 14.0
3e Cl Cl CH2CH3 >30 ND
3f H Cl CH2CH3 3.1 11.8
3g F F CH2CH3 >30 ND
4a CH3 CH3 CH(CH3)2 23.7 ND
4b CH3 H CH(CH3)2 1.9 10.8
4c H H CH(CH3)2 2.0 11.3
4d OCH3 H CH(CH3)2 12.1 ND
4e Cl Cl CH(CH3)2 21.9 ND
4f Cl H CH(CH3)2 17.9 ND
4g F F CH(CH3)2 >30 ND
5a CH3 CH3 C(CH3)3 26.9 ND
5b CH3 H C(CH3)3 2.1 18.9
5c H H C(CH3)3 1.2 8.9
5e Cl Cl C(CH3)3 >30 ND
5f Cl H C(CH3)3 13.7 ND
5g F F C(CH3)3 >30 ND
6a CH3 CH3 C6H5 2.7 ND
6b CH3 H C6H5 1.7 10.0
6d OCH3 H C6H5 23.6 ND
6e Cl Cl C6H5 11.4 ND
6f Cl H C6H5 2.9 ND
6g F F C6H5 >30 ND
Chloroquine sulfate (Sigma) 0.43 ND
 ND: no data.
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selectivity index, with a value of 9. An IC50 value of 8.9
µM was found for 5c and 10.0 µM was the value found for
compound 6b. These results clearly demonstrate poor
selectivity indexes, ranging between 1 and 9, which do not
justify in vivo evaluation of the compounds.
In summary, the screening of the in vitro anti-
malarial activity of 3-trifluoromethyl-2-carbonyl-
quinoxaline di-N-oxide derivatives using cultures of
FcB1 strain of P. falciparum (Chloroquine-resistant)
has permitted the identification of compounds with
expressive activity, although less potent than the
standard chloroquine. However, considering the
originality of this structural pattern as an antimalarial
lead compound, the results described in this paper can
contribute to the designing of new antimalarial drug
candidates that could represent a promising alternative
for treating this negligent disease. Some structural
requirements for the antiplasmodial activity could be
identified, such as the necessity of oxygenation at the
N-1 and N-4 of quinoxaline ring, because no activity
was found for the mono and di-reductive compounds.
Furthermore, the best results were found for 7-methyl
(2b, 4b, 5b, 6b)  and non-substituted (3c, 4c, 5c)
quinoxaline 1,4-dioxide compounds, while the double
pattern of substitution at phenyl ring of quinoxaline
subunit resulted in a loss of activity (e.g. 2e). The
substituents of the carbonyl group did not greatly
influence the antimalarial activity, and consequently,
the considerable steric volume can be well tolerated.
Based on the aforementioned, this structural data is
being used for the optimization of this bioactive series.
This paper describes the antiplasmodial activities of
a novel structure pattern of potential antimalarial drug
candidates and their cytotoxic profiles measured in MCF7
tumor cells bioassay. The quinoxaline di-N-oxide
derivatives 3c, 4b, 4c, 5b, 5c and 6b, with the best
antiplasmodial activity, were demonstrated to possess a
lower selectivity index, ranging between 1 and 9; this
suggests a nonselective cytotoxic profile. A preliminary
study of the structure-activity relationship (SAR) taken
from this work is being used in the optimization of this
bioactive series.
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RESUMO
Atividade antimalárica de derivados di-N-óxido de
3-trifluorometil-2-carbonilquinoxalina
Neste artigo descreve-se a atividade anti-Plasmodium
falciparum de derivados 3-trifluorometil-2-carbonil-
quinoxalinas di-N-óxidos (2a-6g). A avaliação das pro-
priedades farmacológicas dos derivados 2a-6g foi rea-
lizada em modelo in vitro de inibição de cepas P.
falciparum FcB1 (cloroquina resistente) em cultura ce-
lular, e sobre culturas de células tumorais MCF7, com a
finalidade de estabelecer o índice de seletividade para
os compostos mais promissores. Os derivados 7-metil
(2b, 4b, 5b, 6b) e não-substituído (3c, 4c, 5c) apresen-
taram o melhor perfil de atividade.
UNITERMOS: Quinoxalina. Antimalarial. Cloroquina.
MCF7.
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